Inocras Inc.  and Summit Pharmaceuticals International Corporation  (“SPI”) signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing (WGS) analysis services. This collaboration aims to revolutionize healthcare in Japan by leveraging genomic data and bioinformatics to better understand and treat cancer and other genetic conditions.

WGS reads an individual’s entire genome, generating vast data. Inocras' bioinformatics platform transforms this data into actionable clinical insights, enabling precise diagnoses support and personalized treatments. Inocras, a leader in whole-genome sequencing (WGS) and bioinformatics, has partnered with SPI to bring cutting-edge genomic solutions to the Japanese market. In particular, their proprietary technology (*) and bioinformatics pipeline are expected to provide valuable insights in genomic medicine.

(*) Proprietary technology that enables WGS using formalin-fixed paraffin-embedded (FFPE) samples, which are widely utilized in clinical settings.

Inocras and SPI will develop a business plan to integrate WGS into Japan's healthcare system. This effort includes assessing market potential, developing operational models, and evaluating clinical impact. Input from key opinion leaders and other stakeholders will help shape future developments. Future plans include establishing a WGS lab and enhancing local bioinformatics capabilities.

“Inocras is excited to bring advanced WGS and bioinformatics to Japan, offering solutions no other commercial provider delivers here,” said Jehee Suh, CEO of Inocras. “With SPI, we are creating a pathway to improve patient care through data-driven innovation.”

“Japan is at a pivotal point in embracing genomic medicine, and this partnership with Inocras is perfectly timed to help accelerate that transformation,” said Katsuya Okuyama, CEO of SPI